000124294 001__ 124294
000124294 005__ 20240228145504.0
000124294 0247_ $$2doi$$a10.1016/j.jdiacomp.2017.01.002
000124294 0247_ $$2pmid$$apmid:28325697
000124294 0247_ $$2ISSN$$a1056-8727
000124294 0247_ $$2ISSN$$a1873-460X
000124294 0247_ $$2altmetric$$aaltmetric:18159461
000124294 037__ $$aDKFZ-2017-01190
000124294 041__ $$aeng
000124294 082__ $$a610
000124294 1001_ $$aSulaj, Alba$$b0
000124294 245__ $$aALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy.
000124294 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2017
000124294 3367_ $$2DRIVER$$aarticle
000124294 3367_ $$2DataCite$$aOutput Types/Journal article
000124294 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661239352_7133
000124294 3367_ $$2BibTeX$$aARTICLE
000124294 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124294 3367_ $$00$$2EndNote$$aJournal Article
000124294 520__ $$aActivated leukocyte cell adhesion molecule (ALCAM/CD166) functions analogue to the receptor of advanced glycation end products, which has been implicated in the development of diabetic nephropathy (DN). We investigated the expression of ALCAM and its ligand S100B in patients with DN.A total of 34 non-diabetic patients, 29 patients with type 2 diabetes and normal albuminuria and 107 patients with type 2 diabetes complicated with DN were assessed for serum concentration of soluble ALCAM (sALCAM) by ELISA. Expression of ALCAM and S100B in kidney histology from patients with DN was determined by immunohistochemistry. Cell expression of ALCAM and S100B was analyzed through confocal immunofluorescence microscopy.Serum concentration of sALCAM was increased in diabetic patients with DN compared to non-diabetic (59.85±14.99ng/ml vs. 126.88±66.45ng/ml, P<0.0001). Moreover sALCAM correlated positively with HbA1c (R=0.31, P<0.0001), as well as with the stages of chronic kidney disease and negatively correlated with eGFR (R=-0.20, P<0.05). In diabetic patients with normal albuminuria sALCAM was increased compared to patients with DN (126.88±66.45ng/ml vs. 197.50±37.17ng/ml, P<0.0001). In diabetic patients, ALCAM expression was significantly upregulated in both the glomeruli and tubules (P<0.001). ALCAM expression in the glomeruli correlated with presence of sclerosis (R=0.25, P<0.001) and localized mainly in the podocytes supporting the hypothesis that membrane bound ALCAM drives diabetic nephropathy and thus explaining sALCAM decrease in diabetic patients with DN. The expression of S100B was increased significantly in the glomeruli of diabetic patients (P<0.001), but not in the tubules. S100B was as well localized in the podocytes.This study identifies for the first time ALCAM as a potential mediator in the late complications of diabetes in the kidney.
000124294 536__ $$0G:(DE-HGF)POF3-322$$a322 - Genetics and Pathophysiology (POF3-322)$$cPOF3-322$$fPOF III$$x0
000124294 588__ $$aDataset connected to CrossRef, PubMed,
000124294 7001_ $$aKopf, Stefan$$b1
000124294 7001_ $$0P:(DE-He78)b72c4ee15f75cf6944080c339a34475b$$aGröne, Elisabeth$$b2
000124294 7001_ $$0P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aGröne, Hermann-Josef$$b3
000124294 7001_ $$aHoffmann, Sigrid$$b4
000124294 7001_ $$aSchleicher, Erwin$$b5
000124294 7001_ $$aHäring, Hans-Ulrich$$b6
000124294 7001_ $$aSchwenger, Vedat$$b7
000124294 7001_ $$0P:(DE-He78)e527f794b23172e769c8904180546f57$$aHerzig, Stephan$$b8
000124294 7001_ $$aFleming, Thomas$$b9
000124294 7001_ $$0P:(DE-HGF)0$$aNawroth, Peter P$$b10
000124294 7001_ $$avon Bauer, Rüdiger$$b11
000124294 773__ $$0PERI:(DE-600)2006763-X$$a10.1016/j.jdiacomp.2017.01.002$$gVol. 31, no. 6, p. 1058 - 1065$$n6$$p1058 - 1065$$tJournal of diabetes and its complications$$v31$$x1056-8727$$y2017
000124294 909CO $$ooai:inrepo02.dkfz.de:124294$$pVDB
000124294 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b72c4ee15f75cf6944080c339a34475b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124294 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000124294 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e527f794b23172e769c8904180546f57$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000124294 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$aExternal Institute$$b10$$kExtern
000124294 9131_ $$0G:(DE-HGF)POF3-322$$1G:(DE-HGF)POF3-320$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lHerz-Kreislauf-Stoffwechselerkrankungen$$vGenetics and Pathophysiology$$x0
000124294 9141_ $$y2017
000124294 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000124294 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ DIABETES COMPLICAT : 2015
000124294 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124294 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124294 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124294 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000124294 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000124294 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124294 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124294 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124294 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000124294 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124294 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000124294 9201_ $$0I:(DE-He78)G130-20160331$$kG130$$lZelluläre und Molekulare Pathologie$$x0
000124294 980__ $$ajournal
000124294 980__ $$aVDB
000124294 980__ $$aI:(DE-He78)G130-20160331
000124294 980__ $$aUNRESTRICTED